About
About MedRx Co., Ltd
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Visit company website
5 years, 6 months ago
MedRx Co., Ltd is currently in a long term downtrend where the price is trading 20.6% below its 200 day moving average.
From a valuation standpoint, the stock is 35.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 45.3.
MedRx Co., Ltd's total revenue rose by 6027.5% to $100M since the same quarter in the previous year.
Its net income has increased by 68.2% to $-133M since the same quarter in the previous year.
Based on the above factors, MedRx Co., Ltd gets an overall score of 3/5.